An advanced broad-spectrum antibiotic combining Amoxicillin 500mg and Clavulanic Acid 125mg — formulated for effective treatment of dental, respiratory and bacterial infections.
GOBACTO™-625 Tablet is a prescription-only antibiotic developed by Trunexora Healthcare for the management of moderate to severe bacterial infections. It combines the proven efficacy of Amoxicillin (a penicillin-class antibiotic) with Clavulanic Acid (a beta-lactamase inhibitor) — making it effective against beta-lactamase producing resistant bacteria.
GOBACTO™-625 is widely prescribed across dental, respiratory, ENT, urinary and soft tissue infections, offering comprehensive bacterial coverage with a well-established safety profile.
Effective against both gram-positive and gram-negative bacteria.
Clavulanic Acid inhibits beta-lactamase enzymes.
Quick absorption for rapid therapeutic action.
Well-established efficacy with predictable safety profile.
Contraindicated in patients with known hypersensitivity to penicillins or cephalosporins. Use with caution in patients with hepatic impairment, infectious mononucleosis, or history of jaundice associated with amoxicillin/clavulanate. Always consult your physician before use.
| Brand | Trunexora Healthcare |
|---|---|
| Category | Antibiotic (Rx) |
| Form | Film-coated Tablet |
| Strength | 500 mg + 125 mg |
| Pack Size | Strip of 10 / 6 tablets |
| Manufacturing Standard | GMP / WHO-GMP |
| Country of Origin | India |
